(CC) Chemours - Overview
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: NYSE (USA) | Market Cap: 3.085m USD | Total Return: 101.3% in 12m
Avg Turnover: 73.9M
EPS Trend: -93.1%
Qual. Beats: -1
Rev. Trend: -73.3%
Qual. Beats: -1
Warnings
High Debt/EBITDA (8.0) with thin interest coverage (0.7)
Interest Coverage Ratio 0.7 is critical
Below Avwap Earnings
Tailwinds
Leader
The Chemours Company is a global industrial manufacturer specializing in performance chemicals across three core segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. The company holds significant market positions through established brands such as Freon, Opteon, Ti-Pure, and Teflon, serving diverse end-markets including semiconductors, automotive, and consumer electronics.
Operating within the diversified chemicals sector, Chemours utilizes a vertically integrated business model to produce Titanium Dioxide (TiO2), a critical industrial chemical used primarily for opacity and durability in coatings and plastics. The chemical industry is characterized by high capital intensity and cyclical demand, where profitability often depends on raw material costs and global industrial production rates.
Investors can further evaluate the companys historical valuation trends and peer comparisons on ValueRay. The company distributes its product portfolio through a combination of direct sales and a global network of third-party distributors to maintain its presence in North America, Asia Pacific, and Europe.
- Fluctuating global demand for titanium dioxide impacts core revenue and pricing power
- Environmental litigation costs and PFAS regulatory settlements pressure balance sheet stability
- Opteon refrigerant adoption rates drive growth in Thermal and Specialized Solutions
- Semiconductor and clean energy demand fuels high-margin Advanced Performance Materials sales
- Raw material costs and energy price volatility affect consolidated manufacturing margins
| Net Income: -411.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 12.90 > 1.0 |
| NWC/Revenue: 22.66% < 20% (prev 21.66%; Δ 1.00% < -1%) |
| CFO/TA 0.05 > 3% & CFO 332.0m > Net Income -411.0m |
| Net Debt (4.08b) to EBITDA (510.0m): 8.00 < 3 |
| Current Ratio: 1.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (150.6m) vs 12m ago 0.09% < -2% |
| Gross Margin: 15.13% > 18% (prev 0.19%; Δ 1.49k% > 0.5%) |
| Asset Turnover: 79.41% > 50% (prev 78.67%; Δ 0.74% > 0%) |
| Interest Coverage Ratio: 0.66 > 6 (EBITDA TTM 510.0m / Interest Expense TTM 271.0m) |
| A: 0.18 (Total Current Assets 2.93b - Total Current Liabilities 1.61b) / Total Assets 7.27b |
| B: 0.16 (Retained Earnings 1.18b / Total Assets 7.27b) |
| C: 0.02 (EBIT TTM 179.0m / Avg Total Assets 7.33b) |
| D: 0.13 (Book Value of Equity 936.0m / Total Liabilities 7.05b) |
| Altman-Z'' = 2.02 = BBB |
| DSRI: 0.88 (Receivables 759.0m/858.0m, Revenue 5.82b/5.82b) |
| GMI: 1.25 (GM 15.13% / 18.96%) |
| AQI: 1.00 (AQ_t 0.14 / AQ_t-1 0.14) |
| SGI: 1.00 (Revenue 5.82b / 5.82b) |
| TATA: -0.10 (NI -411.0m - CFO 332.0m) / TA 7.27b) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of May 24, 2026, the stock is trading at USD 21.44 with a total of 3,313,215 shares traded.
Over the past week, the price has changed by -7.61%,
over one month by -10.79%,
over three months by +19.55% and
over the past year by +101.28%.
Chemours has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold CC.
- StrongBuy: 3
- Buy: 2
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 25.8 | 20.2% |
P/S = 0.53
P/B = 15.5763
P/EG = 1.6042
Revenue TTM = 5.82b USD
EBIT TTM = 179.0m USD
EBITDA TTM = 510.0m USD
Long Term Debt = 4.10b USD (from longTermDebt, last quarter)
Short Term Debt = 99.0m USD (from shortTermDebt, last quarter)
Debt = 4.64b USD (from shortLongTermDebtTotal, last quarter) + Leases 254.0m
Net Debt = 4.08b USD (calculated: Debt 4.64b - CCE 563.0m)
Enterprise Value = 7.17b USD (3.08b + Debt 4.64b - CCE 563.0m)
Interest Coverage Ratio = 0.66 (Ebit TTM 179.0m / Interest Expense TTM 271.0m)
EV/FCF = 46.54x (Enterprise Value 7.17b / FCF TTM 154.0m)
FCF Yield = 2.15% (FCF TTM 154.0m / Enterprise Value 7.17b)
FCF Margin = 2.65% (FCF TTM 154.0m / Revenue TTM 5.82b)
Net Margin = -7.06% (Net Income TTM -411.0m / Revenue TTM 5.82b)
Gross Margin = 15.13% ((Revenue TTM 5.82b - Cost of Revenue TTM 4.94b) / Revenue TTM)
Gross Margin QoQ = 15.57% (prev 11.50%)
Tobins Q-Ratio = 0.99 (Enterprise Value 7.17b / Total Assets 7.27b)
Interest Expense / Debt = 5.83% (Interest Expense 271.0m / Debt 4.64b)
Taxrate = 21.0% (US default 21%)
NOPAT = 141.4m (EBIT 179.0m * (1 - 21.00%))
Current Ratio = 1.82 (Total Current Assets 2.93b / Total Current Liabilities 1.61b)
Debt / Equity = 21.60 (Debt 4.64b / totalStockholderEquity, last quarter 215.0m)
Debt / EBITDA = 8.00 (Net Debt 4.08b / EBITDA 510.0m)
Debt / FCF = 26.51 (Net Debt 4.08b / FCF TTM 154.0m)
Total Stockholder Equity = 250.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.61% (Net Income -411.0m / Total Assets 7.27b)
RoE = -164.4% (Net Income TTM -411.0m / Total Stockholder Equity 250.0m)
RoCE = 4.11% (EBIT 179.0m / Capital Employed (Equity 250.0m + L.T.Debt 4.10b))
RoIC = 2.52% (NOPAT 141.4m / Invested Capital 5.62b)
WACC = 7.89% (E(3.08b)/V(7.73b) * Re(12.82%) + D(4.64b)/V(7.73b) * Rd(5.83%) * (1-Tc(0.21)))
Discount Rate = 12.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 70.47 | Cagr: 0.59%
[DCF] Terminal Value 75.44% ; FCFF base≈154.0m ; Y1≈154.6m ; Y5≈163.8m
[DCF] Fair Price = N/A (negative equity: EV 2.55b - Net Debt 4.08b = -1.53b; debt exceeds intrinsic value)
EPS Correlation: -93.11 | EPS CAGR: -35.71% | SUE: -1.32 | # QB: -1
Revenue Correlation: -73.31 | Revenue CAGR: -1.97% | SUE: -0.86 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.43 | Chg30d=-31.08% | Revisions=-64% | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.55 | Chg30d=-3.09% | Revisions=-27% | Analysts=9
EPS current Year (2026-12-31): EPS=1.30 | Chg30d=-9.94% | Revisions=-9% | GrowthEPS=+36.6% | GrowthRev=+4.2%
EPS next Year (2027-12-31): EPS=2.27 | Chg30d=-0.92% | Revisions=-27% | GrowthEPS=+75.0% | GrowthRev=+5.8%
[Analyst] Revisions Ratio: -64%